Literature DB >> 9918912

Altered Gq/G11 guanine nucleotide regulatory protein expression in a rat model of hepatocellular carcinoma: role in mitogenesis.

I H McKillop1, C M Schmidt, P A Cahill, J V Sitzmann.   

Abstract

Guanine nucleotide regulatory proteins (G-proteins) represent an important transmembrane pathway whereby extra-cellular signals are transduced to intracellular signaling pathways. The mitogen-activated protein kinase (MAPK) cascade has been identified as a key factor in transducing numerous mitogenic stimuli. MAPK activity is regulated via numerous receptor types, including those linked to Gq/G11-proteins, which regulate phospholipase-C activity. We hypothesized that alterations in a Gq/G11-PLC pathway may contribute to the enhanced cellular mitogenesis characteristic of hepatocellular carcinoma (HCC), possibly via a MAPK-dependent pathway. By using an in vivo model of HCC we investigated changes in Gq/G11-protein expression in tumorigenic tissue versus adjacent, non-neoplastic liver. In addition we addressed the role of Gq/G11-proteins in the regulation of MAPK-linked mitogenesis by using rat hepatic tumorigenic cells (H4IIE) and isolated hepatocytes in culture. Western blot analysis showed significant increases in Gqalpha and G11alpha expression in tumorigenic liver versus normal liver specimens, an effect that was augmented in cultured H4IIE cells versus isolated cultured hepatocytes. Furthermore, phosphoinositol specific phospholipase-C (PLC) activity was significantly increased in HCC versus normal liver. A specific PLC inhibitor (Et-18-OCH3) caused a dose-dependent decrease in serum stimulated DNA synthesis in both cultured H4IIE cells and isolated rat hepatocytes, the H4IIE cell line showing greater sensitivity to Et-18-OCH3. In addition, serum-stimulated MAPK activity was significantly enhanced in H4IIE versus cultured hepatocytes. Moreover, treatment with Et-18-OCH3 significantly attenuated serum stimulated MAPK activity in both cultured hepatocytes and H4IIE cells. Furthermore, U73122 (Gqalpha-PLC specific uncoupler) and GP2A (Gqalpha specific inhibitor) mirrored the effects of those observed for Et-18-OCH3 whereas PD98059 (specific MEK inhibitor) completely abolished serum-stimulated DNA synthesis in tumorigenic H4IIE cells. We conclude that HCC is associated with enhanced Gq/G11-PLC expression/activity as compared with normal liver. Furthermore, a PLC-linked MAPK cascade plays a significant role in the progression of the enhanced mitogenesis characteristic of HCC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9918912     DOI: 10.1002/hep.510290201

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  3 in total

1.  Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans.

Authors:  Dianke Yu; Leihong Wu; Pritmohinder Gill; William H Tolleson; Si Chen; Jinchun Sun; Bridgett Knox; Yaqiong Jin; Wenming Xiao; Huixiao Hong; Yong Wang; Zhen Ren; Lei Guo; Nan Mei; Yongli Guo; Xi Yang; Leming Shi; Yinting Chen; Linjuan Zeng; Kostiantyn Dreval; Volodymyr Tryndyak; Igor Pogribny; Hong Fang; Tieliu Shi; Sandra McCullough; Sudeepa Bhattacharyya; Laura Schnackenberg; William Mattes; Richard D Beger; Laura James; Weida Tong; Baitang Ning
Journal:  Arch Toxicol       Date:  2017-10-24       Impact factor: 5.153

2.  The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.

Authors:  Patrick J Klein; C Max Schmidt; Chad A Wiesenauer; Jennifer N Choi; Earl A Gage; Michele T Yip-Schneider; Eric A Wiebke; Yufang Wang; Charles Omer; Judith S Sebolt-Leopold
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

3.  Cyclosporin A activates human hepatocellular carcinoma (HepG2 cells) proliferation: implication of EGFR-mediated ERK1/2 signaling pathway.

Authors:  Mohammed E Abo-El Fetoh; Gouda K Helal; I G Saleh; M Ewees; Mohamed ElShafey; Mohamed R Elnagar; El-Sayed Akool
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-01-06       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.